R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition

被引:3
|
作者
Sears, Thomas K. [1 ]
Woolard, Kevin D. [2 ]
机构
[1] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[2] UC Davis Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA USA
关键词
Mutant isocitrate dehydrogenase 1; 2 (IDH1; 2); Glioma; Bromodomain inhibition; Bromodomain and extraterminal (BET); JQ1; BRD4; PLURIPOTENCY; JQ1;
D O I
10.1007/s00432-022-04018-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Mutations in isocitrate dehydrogenase 1/2 (IDHmut) identify a subset of gliomas that exhibit epigenetic dysregulation via aberrant DNA methylation. These tumors are ultimately fatal and lack effective therapeutic strategies. Considering the epigenetic dysregulation of IDHmut gliomas, we hypothesized that epigenetic-targeting drugs may yield therapeutic benefits in gliomas bearing IDHmut. One set of targets includes the bromodomain and extraterminal (BET) family of transcriptional coactivators. Methods We used TCGA data from glioma patients to determine whether BET proteins affect patient survival differently based on IDH status. Follow-up experiments using a set of IDH wildtype/mutant glioma cultures, as well as an IDH wildtype glioblastoma cell line expressing exogenous R132H IDH1, focused on cell health assays to investigate whether IDHmut was associated with increased sensitivity to the BET inhibitor JQ1. Immunoblots were used to evaluate the molecular response to JQ1 in these cultures. Results We identified that high BRD4 expression associated with decreased survival only in IDHmut glioma patients. Cell viability analysis showed that IDHmut sensitized glioma cells to delayed cytotoxicity (10 days) in response to JQ1. Early effects of JQ1 (3 days) were primarily antiproliferative, with IDHmut glioma exhibiting a modest increase in sensitivity. Finally, exogenous R132H IDH1 expression in a resistant IDH wildtype cell line recapitulated the JQ1-mediated delayed cytotoxicity seen in our endogenous IDHmut glioma cells. Conclusion Overall, these data suggest that BRD4 enhances malignancy primarily in gliomas bearing IDHmut and is associated with greater sensitivity to BET inhibition. The finding that BET inhibition primarily exhibits delayed cytotoxicity may be overlooked in conventional short endpoint dose-response assays. Follow-up mechanistic and animal studies will help address the translational potential of these findings.
引用
收藏
页码:2275 / 2285
页数:11
相关论文
共 50 条
  • [31] Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
    Olar, Adriana
    Raghunathan, Aditya
    Albarracin, Constance T.
    Aldape, Kenneth D.
    Cahill, Daniel P., III
    Powell, Suzanne Z.
    Goodman, J. Clay
    Fuller, Gregory N.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2012, 16 (03) : 161 - 170
  • [32] Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens
    Preusser, Matthias
    Woehrer, Adelheid
    Stary, Susanne
    Hoeftberger, Romana
    Streubel, Berthold
    Hainfellner, Johannes A.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2011, 70 (08) : 715 - 723
  • [33] Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan, Sevin
    Fabius, Armida W. M.
    Borodovsky, Alexandra
    Pedraza, Alicia
    Brennan, Cameron
    Huse, Jason
    Viale, Agnes
    Riggins, Gregory J.
    Chan, Timothy A.
    ONCOTARGET, 2013, 4 (10) : 1729 - 1736
  • [34] IDH1R132H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a
    Nie, Quan-Min
    Lin, Ying-Ying
    Yang, Xi
    Shen, Lin
    Guo, Lie-Mei
    Que, Shuang-Lin
    Li, Xiao-Xiong
    Ge, Jian-Wei
    Wang, Gui-Song
    Xiong, Wen-Hao
    Guo, Pin
    Qiu, Yong-Ming
    MOLECULAR MEDICINE REPORTS, 2015, 12 (05) : 6695 - 6701
  • [35] The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells
    Xu, Hui
    Cao, Yu
    Ruan, Jianqiao
    Wang, Fei
    He, Yuhong
    Yang, Lina
    Yu, Tian
    Du, Fang
    Zhang, Ningmei
    Cao, Xiangmei
    JOURNAL OF NEURO-ONCOLOGY, 2024, 170 (01) : 161 - 171
  • [36] Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas
    Kaishi Satomi
    Akihiko Yoshida
    Yuko Matsushita
    Hirokazu Sugino
    Kenji Fujimoto
    Mai Honda-Kitahara
    Masamichi Takahashi
    Makoto Ohno
    Yasuji Miyakita
    Yoshitaka Narita
    Yasushi Yatabe
    Junji Shibahara
    Koichi Ichimura
    Brain Tumor Pathology, 2022, 39 : 210 - 217
  • [37] Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo
    Huang, Guo-dong
    Chen, Fan-fan
    Ma, Guo-Xu
    Li, Wei-ping
    Zheng, Yue-yang
    Meng, Xiang-bao
    Li, Zong-yang
    Chen, Lei
    PHYTOMEDICINE, 2021, 82
  • [38] Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas
    Satomi, Kaishi
    Yoshida, Akihiko
    Matsushita, Yuko
    Sugino, Hirokazu
    Fujimoto, Kenji
    Honda-Kitahara, Mai
    Takahashi, Masamichi
    Ohno, Makoto
    Miyakita, Yasuji
    Narita, Yoshitaka
    Yatabe, Yasushi
    Shibahara, Junji
    Ichimura, Koichi
    BRAIN TUMOR PATHOLOGY, 2022, 39 (04) : 210 - 217
  • [39] IDH1R132H mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status
    Kessler, Jacqueline
    Guettler, Antje
    Wichmann, Henri
    Rot, Swetlana
    Kappler, Matthias
    Bache, Matthias
    Vordermark, Dirk
    RADIOTHERAPY AND ONCOLOGY, 2015, 116 (03) : 381 - 387
  • [40] Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
    Cai, Jinquan
    Zhu, Ping
    Zhang, Chuanbao
    Li, Qingbin
    Wang, Zhiliang
    Li, Guanzhang
    Wang, Guangzhi
    Yang, Pei
    Li, Jianlong
    Han, Bo
    Jiang, Chuanlu
    Sun, Ying
    Jiang, Tao
    ONCOTARGET, 2016, 7 (13) : 16384 - 16395